Montelukast as add-on treatment to intranasal steroids does not show a major clinical efficacy in nasal polyps

被引：0
|
作者：
Van Gerven, L. [1 ]
Jorissen, M. [1 ]
Fokkens, W. [2 ]
Hellings, P. [1 ]
机构：
[1] Univ Hosp Leuven, Louvain, Belgium
[2] Univ Hosp Amsterdam, Amsterdam, Netherlands
来源：
ALLERGY | 2011年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
48
引用
收藏
页码：22 / 23
页数：2
相关论文
共 39 条
  • [31] Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial
    Wessa, C.
    Janssens, J.
    Coppens, V.
    El Abdellati, K.
    Vergaelen, E.
    van den Ameele, S.
    Baeken, C.
    Zeeuws, D.
    Milaneschi, Y.
    Lamers, F.
    Penninx, B.
    Claes, S.
    Morrens, M.
    De Picker, L.
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2024, 41
  • [32] Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial
    Simon, Maria S.
    Burger, Bianka
    Weidinger, Elif
    Arteaga-Henriquez, Gara
    Zill, Peter
    Musil, Richard
    Drexhage, Hemmo A.
    Mueller, Norbert
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [33] Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies
    Gil-Nagel, Antonio
    Elger, Christian
    Ben-Menachem, Elinor
    Halasz, Peter
    Lopes-Lima, Jose
    Gabbai, Alberto A.
    Nunes, Teresa
    Falcao, Amilcar
    Almeida, Luis
    Soares-da-Silva, Patricio
    EPILEPSIA, 2013, 54 (01) : 98 - 107
  • [34] Evaluating efficacy and safety of Saffron add-on treatment in improvement of motor and depressive symptoms of patients with Parkinson's disease: A randomized, double-blind, placebo-controlled clinical trial
    Lalezari, Vahirezad
    Aghamollaii, Vajiheh
    Moslehi, Ahmadreza
    Najafi, Amir
    Parsaei, Mohammadamin
    Beikmarzehei, Alireza
    Moghaddam, Hossein Sanjari
    Abdolghaffari, Amir Hossein
    Akhondzadeh, Shahin
    JOURNAL OF HERBAL MEDICINE, 2024, 48
  • [35] Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial
    Kamperman, Renske G.
    Bogaards, Johannes A.
    Evers, Sanne W.
    Walter, Hannah A. W.
    de Visser, Marianne
    de Borgie, Corianne
    de Koning, Jantine C. A. Colen
    Verhamme, Camiel
    Maas, Mario
    Eftimov, Filip
    van Schaik, Ivo N.
    van der Kooi, Anneke J.
    Raaphorst, Joost
    BMJ OPEN, 2023, 13 (07):
  • [36] A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
    Lombardo, Flavia L.
    Alegiani, Stefania Spila
    Mayer, Flavia
    Cipriani, Marta
    Lo Giudice, Maria
    Ludolph, Albert Christian
    McDermott, Christopher J.
    Corcia, Philippe
    Van Damme, Philip
    van den Berg, Leonard H.
    Hardiman, Orla
    Nicolini, Gabriele
    Vanacore, Nicola
    Dickie, Brian
    Albanese, Alberto
    Puopolo, Maria
    TRIALS, 2023, 24 (01)
  • [37] Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies
    Elger, Christian
    Koepp, Mathias
    Trinka, Eugen
    Villanueva, Vicente
    Chaves, Joao
    Ben-Menachen, Elinor
    Kowacs, Pedro A.
    Gil-Nagel, Antonio
    Moreira, Joana
    Gama, Helena
    Rocha, Jose-Francisco
    Soares-da-Silva, Patricio
    CNS NEUROSCIENCE & THERAPEUTICS, 2017, 23 (12) : 961 - 972
  • [38] A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
    Flavia L. Lombardo
    Stefania Spila Alegiani
    Flavia Mayer
    Marta Cipriani
    Maria Lo Giudice
    Albert Christian Ludolph
    Christopher J. McDermott
    Philippe Corcia
    Philip Van Damme
    Leonard H. Van den Berg
    Orla Hardiman
    Gabriele Nicolini
    Nicola Vanacore
    Brian Dickie
    Alberto Albanese
    Maria Puopolo
    Trials, 24
  • [39] Prospective, Randomized, Open-Label, Blinded End Point, Two-Arm, Comparative Clinical Study to Evaluate the Efficacy and Safety of a Fixed Ayurvedic Regimen (FAR) as Add-on to Conventional Treatment in the Management of Mild and Moderate COVID-19 Patients
    Gupta, Arun
    Vedula, Sasibhushan
    Srivastava, Ruchi
    Tamoli, Sanjay
    Mundhe, Narendra
    Wagh, D. N.
    Batra, Sanjay
    Patil, Manoj
    Pawar, Hiren Baburao
    Rai, Rajiva K.
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2021, 13 (02): : 256 - 267
1234